Connect Biopharma Holdings Ltd

Director and Officer Trading Arrangements

A portion of the compensation of certain of the Company’s directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) is in the form of equity awards and, from time to time, directors and officers may engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or other Company securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.

Transactions in Company securities by directors and officers are required to be made in accordance with the Company’s Insider Trading Compliance Policy, which requires, among other things, that such transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in the Company’s securities in a manner intended to avoid concerns about initiating transactions while in possession of material nonpublic information.

On December 18, 2025, as part of the National Defense Authorization Act for Fiscal Year 2026, the Holding Foreign Insiders Accountable Act (the “HFIAA”) was signed into law. The HFIAA amended Section 16(a) of the Exchange Act to require directors and officers of foreign private issuers to comply with the insider reporting requirements set forth in Section 16(a) of the Exchange Act, beginning March 18, 2026. As a result, the Company is making this disclosure pursuant to Item 408(b) of Regulation S-K for the first time.

During the fourth fiscal quarter of our fiscal year ended December 31, 2025, none of our directors or officers adopted orterminated a (i) Rule 10b5-1 trading arrangement (as defined in Item 408(a) of Regulation S-K) or (ii) non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).